Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 6/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226941 | 0.88 | CCR2 (0.40) | MEN1KMT2ACCR2EPHX2ALDH1A1 | |
| SCHEMBL1779888 | 0.78 | MEN1 (0.37) | MEN1KMT2ACCR2EPHX2HPGD | |
| SCHEMBL1780501 | 0.77 | CCR2 (0.47) | MEN1KMT2ACCR2HPGDALDH1A1 | |
| SCHEMBL1781978 | 0.74 | CCR2 (0.42) | MEN1KMT2ACCR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1781064 | 0.71 | SLC6A3 (0.46) | CCR2SLC6A4SLC6A3 | |
| SCHEMBL3233210 | 0.71 | CCR2 (0.49) | CCR2ALDH1A1SLC6A3 | |
| SCHEMBL3235269 | 0.69 | CCR2 (0.40) | MEN1KMT2ACCR2EPHX2ALDH1A1 | |
| SCHEMBL1779902 | 0.69 | CCR2 (0.40) | MEN1KMT2ACCR2EPHX2ALDH1A1 | |
| SCHEMBL1778995 | 0.68 | CCR2 (0.44) | CCR2SLC6A4SLC6A3 | |
| SCHEMBL1781951 | 0.64 | CCR2 (0.81) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| EP-2318352-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | MEN1 4508/4885KMT2A 3653/4885CCR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.